Sang froid in a time of trouble: Is a vaccine against HIV possible?

Journal of the International AIDS Society

Volumn 12, Issue 1, 2009, Pages

  Plotkin, Stanley A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MUCOSAL IMMUNITY; NOTE; PRIORITY JOURNAL; VACCINATION; VIRUS LOAD;

EID: 76949097646     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-12-2     Document Type: Note

References (139)

1. Plotkin SA, Farquhar JD, Katz M, Buser F: Attenuation of RA 27-3 rubella virus in WI-38 human diploid cells. Am J Dis Child 1969, 118(2):178-185.
2. Plotkin SA, Farquhar JD, Ogra PL: Immunologic properties of RA27/3 rubella virus vaccine. Journal of American Medical Association 1973, 225:585-590.
3. Fogel A, Gerichter CB, Barnea B, Handsher R, Heeger E: Response to experimental challenge in persons immunized with different rubella vaccines. J Pediatr 1978, 92(1):26-29.
4. Polack FP: Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res 2007, 62(1):111-115.
5. Polack FP, Hoffman SJ, Moss WJ, Griffin DE: Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles. J Infect Dis 2002, 185(1):13-19.
6. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE: A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003, 9(9):1209-1213.
7. De Swart RL, Kuiken T, Timmerman HH, van AG, Hoogen BG Van Den, Vos HW, et al.: Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 2002, 76(22):11561-11569.
8. Tregoning JS, Yamaguchi Y, Harker J, Wang B, Openshaw PJ: The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol 2008, 82(8):4115-4124.
9. Intussusception among recipients of rotavirus vaccine – United States, 1998–1999. MMWR Morb Mortal Wkly Rep 1999, 48(27):577-581.
10. Joensuu J, Koskenniemi E, Vesikari T: Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998, 17(4):334-340.
11. Clark HF, Offit PA, Plotkin SA, Heaton PM: The new pentavalent rotavirus vaccine composed of bovine (strain WC3) – human rotavirus reassortants. Pediatr Infect Dis J 2006, 25(7):577-583.
12. Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL: Protection from rotavirus reinfections: two-year prospective study. J Infect Dis 1991, 164:277-283.
13. Vesikari T, Matson DO, Dennehy P, Van DP, Santosham M, Rodriguez Z, et al.: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
14. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al.: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
15. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R: Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004, 39(2):233-239.
16. Plotkin SA: Is there a formula for an effective CMV vaccine? J Clin Virol 2002, 25(Suppl 2):S13-S21.
17. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE: Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989, 159(5):860-865.
18. Pass R, Zhang C, Simpson T, et al.: Cytomegalovirus (CMV) envelope glycoprotein B (gB) vaccine in young women. [Abstract]. Infectious Diseases Society of America, (late-breaker), San Diego, CA, October 4–7, 2007 2007.
19. Blish CA, Blay WM, Haigwood NL, Overbaugh J: Transmission of HIV-1 in the face of neutralizing antibodies. Curr HIV Res 2007, 5(6):578-587.
20. Piantadosi A, Ngayo MO, Chohan B, Overbaugh J: Examination of a Second Region of the HIV Type 1 Genome Reveals Additional Cases of Superinfection. AIDS Res Hum Retroviruses 2008, 24(9):1221.
21. Plotkin SA: Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47(3):401-409.
22. Simmonds P: Genetic diversity and evolution of hepatitis C virus – 15 years on. J Gen Virol 2004, 85(Pt 11):3173-3188.
23. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, et al.: Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007, 104(14):6025-6030.
24. Houghton M, Abrignani S: Prospects for a vaccine against the hepatitis C virus. Nature 2005, 436(7053):961-966.
25. Von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, et al.: Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007, 132(2):667-678.
26. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, et al.: Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007, 104(20):8427-8432.
27. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001, 194(10):1395-1406.
28. Thimme R, Neumann-Haefelin C, Boettler T, Blum HE: Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem 2008, 389(5):457-67.
29. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohren-wend P, et al.: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000, 191(9):1499-1512.
30. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al.: Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001, 33(6):1479-1487.
31. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al.: Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003, 197(12):1645-1655.
32. Yerly D, Heckerman D, Allen TM, Chisholm JV III, Faircloth K, Linde CH, et al.: Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol 2008, 82(6):3147-3153.
33. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A: Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008, 8(6):379-386.
34. Lin Y, Kwon T, Polo J, Zhu YF, Coates S, Crawford K, et al.: Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008, 82(15):7492-7503.
35. Lehner T, Wang Y, Pido-Lopez J, Whittall T, Bergmeier LA, Babaahmady K: The emerging role of innate immunity in protection against HIV-1 infection. Vaccine 2008, 26(24):2997-3001.
36. Pido-Lopez J, Whittall T, Wang Y, Bergmeier LA, Babaahmady K, Singh M, et al.: Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells. J Immunol 2007, 178(3):1671-1679.
37. Vieillard V, Le GR, Dausset J, Debre P: A vaccine strategy against AIDS: an HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques. Proc Natl Acad Sci USA 2008, 105(6):2100-2104.
38. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, et al.: Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 2008, 321(5894):1343-1346.
39. Miconnet I, Pantaleo G: A soluble hexameric form of CD40 lig-and activates human dendritic cells and augments memory T cell response. Vaccine 2008, 26(32):4006-4014.
40. Liu J, Yu Q, Stone GW, Yue FY, Ngai N, Jones RB, et al.: CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008, 26(32):4062-4072.
41. Johnston MI, Fauci AS: An HIV vaccine – evolving concepts. N Engl J Med 2007, 356(20):2073-2081.
42. Burioni R, Mancini N, De MD, Clementi N, Perotti M, Nitti G, et al.: Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS ONE 2008, 3(10):e3423.
43. Babaahmady K, Bergmeier LA, Lehner T: Combining human antisera to human leukocyte antigens, HIVgp120 and 70 kDa heat shock protein results in broadly neutralizing activity to HIV-1. AIDS 2008, 22(11):1267-1276.
44. Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR: Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 2002, 76(17):8769-8775.
45. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT: The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008, 6(2):143-155.
46. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, et al.: Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194(12):1650-1660.
47. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, et al.: Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005, 79(5):2956-2963.
48. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, et al.: Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006, 350(1):34-47.
49. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, et al.: Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008, 26(31):3947-3957.
50. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al.: Protection of macaques against pathogenic simian/ human immunodeficiency virus 89.6 PD by passive transfer of neutralizing antibodies. J Virol 1999, 73(5):4009-4018.
51. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6(2):207-210.
52. Mascola JR: Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002, 20(15):1922-1925.
53. Yamamoto H, Kawada M, Takeda A, Igarashi H, Matano T: Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS ONE 2007, 2(6):e540.
54. Barin F, Jourdain G, Brunet S, Ngo-Giang-Huong N, Weerawat-goompa S, Karnchanamayul W, et al.: Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J Infect Dis 2006, 193(11):1504-1511.
55. Bjorling E, Scarlatti G, von GA, Albert J, Biberfeld G, Chiodi F, et al.: Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993, 193(1):528-530.
56. Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, et al.: Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 86(Pt 12):3385-3396.
57. Leligdowicz A, Rowland-Jones S: Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection. Expert Rev Vaccines 2008, 7(3):319-331.
58. Trkola A, Kuster H, Rusert P, von WV, Leemann C, Weber R, et al.: In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 2008, 82(3):1591-1599.
59. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al.: Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11(6):615-622.
60. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, et al.: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001, 75(17):8340-8347.
61. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, et al.: Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002, 76(5):2123-2130.
62. Smith DM, Strain MC, Frost SD, Pillai SK, Wong JK, Wrin T, et al.: Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006, 355(1):1-5.
63. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008, 105(21):7552-7557.
64. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, et al.: Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005, 79(14):9217-9227.
65. Zhang PF, Cham F, Dong M, Choudhary A, Bouma P, Zhang Z, et al.: Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci USA 2007, 104(24):10193-10198.
66. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, et al.: Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 2006, 80(12):6155-6164.
67. Sattentau Q: Correlates of antibody-mediated protection against HIV infection. Current Opinion in HIV and AIDS 2008, 3:368-374.
68. Brown BK, Wieczorek L, Sanders-Buell E, Rosa BA, Robb ML, Birx DL, et al.: Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008, 375(2):529-538.
69. Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lifton MA, Lord CI, et al.: Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol 1999, 162(9):5127-5133.
70. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, Furlott J, et al.: Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006, 80(12):5875-5885.
71. Deeks SG, Walker BD: Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27(3):406-416.
72. Hess C, Altfeld M, Thomas SY, Addo MM, Rosenberg ES, Allen TM, et al.: HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 2004, 363(9412):863-866.
73. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283(5403):857-860.
74. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68(9):6103-6110.
75. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, Bean AT, et al.: Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007, 178(5):2746-2754.
76. Lifson JD, Rossio JL, Piatak M Jr, Parks T, Li L, Kiser R, et al.: Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 2001, 75(21):10187-10199.
77. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al.: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(12):4781-4789.
78. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al.: Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008, 197(4):563-571.
79. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al.: HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007, 104(16):6776-6781.
80. Piacentini L, Fenizia C, Naddeo V, Clerici M: Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine 2008, 26(24):3002-3007.
81. Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, et al.: Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007, 81(24):13904-13915.
82. Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF: Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol 2008, 82(17):8307-8315.
83. Kulkarni PS, Butera ST, Duerr AC: Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003, 5(2):87-103.
84. Miller JD, Most RG van der, Akondy RS, Glidewell JT, Albott S, Masopust D, et al.: Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28(5):710-722.
85. Turk G, Gherardi MM, Laufer N, Saracco M, Luzzi R, Cox JH, et al.: Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol 2008, 82(6):2853-2866.
86. Critchfield JW, Lemongello D, Walker DH, Garcia JC, Asmuth DM, Pollard RB, et al.: Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol 2007, 81(11):5460-5471.
87. Kawada M, Igarashi H, Takeda A, Tsukamoto T, Yamamoto H, Dohki S, et al.: Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J Virol 2006, 80(4):1949-1958.
88. Sun Y, Santra S, Schmitz JE, Roederer M, Letvin NL: Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys. J Virol 2008, 82(17):8812-8819.
89. Daucher M, Price DA, Brenchley JM, Lamoreaux L, Metcalf JA, Rehm C, et al.: Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. J Virol 2008, 82(8):4102-4114.
90. Bennett MS, Ng HL, Dagarag M, Ali A, Yang OO: Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol 2007, 81(10):4973-4980.
91. Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA: A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 2007, 178(11):7211-7221.
92. Kawada M, Tsukamoto T, Yamamoto H, Takeda A, Igarashi H, Watkins DI, et al.: Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J Virol 2007, 81(10):5202-5211.
93. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, et al.: Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007, 13(1):100-106.
94. Santra S, Korber BT, Muldoon M, Barouch DH, Nabel GJ, Gao F, et al.: A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci USA 2008, 105(30):10489-10494.
95. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, et al.: Differential Th17 CD4 T cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008.
96. Sun Y, Schmitz JE, Buzby AP, Barker BR, Rao SS, Xu L, et al.: Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 2006, 80(22):10950-10956.
97. Ruggiero E, Bona R, Muratori C, Federico M: Virological consequences of early events following cell-cell contact between human immunodeficiency virus type 1-infected and uninfected CD4+ cells. J Virol 2008, 82(16):7773-7789.
98. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Pre-blud SR, et al.: Measles antibody: reevaluation of protective titers. J Infect Dis 1990, 162(5):1036-1042.
99. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, et al.: Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181(3):1133-1137.
100. Haynes BF, Shattock RJ: Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 2008, 122(1):3-9.
101. Girard MP, Bansal GP, Pedroza-Martins L, Dodet B, Mehra V, Schito M, et al.: Mucosal immunity and HIV/AIDS vaccines: Report of an International Workshop, 28–30 October 2007. Vaccine 2008, 26(32):3969-3977.
102. Bouvet JP, Fischetti VA: Diversity of antibody-mediated immunity at the mucosal barrier. Infect Immun 1999, 67(6):2687-2691.
103. Shattock RJ, Haynes BF, Pulendran B, Flores J, Esparza J: Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 2008, 5(4):e81.
104. Brandtzaeg P: Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25(30):5467-5484.
105. Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, Prince SJ, et al.: Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004, 20(9):972-988.
106. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, et al.: Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280(5362):427-431.
107. Ling B, Veazey RS, Hart M, Lackner AA, Kuroda M, Pahar B, et al.: Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression. AIDS 2007, 21(18):2377-2385.
108. Kallewaard NL, McKinney BA, Gu Y, Chen A, Prasad BV, Crowe JE Jr: Functional maturation of the human antibody response to rotavirus. J Immunol 2008, 180(6):3980-3989.
109. Garaicoechea L, Olichon A, Marcoppido G, Wigdorovitz A, Mozgovoj M, Saif L, et al.: Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice. J Virol 2008, 82(19):9753-9764.
110. Yuan L, Wen K, Azevedo MS, Gonzalez AM, Zhang W, Saif LJ: Virus-specific intestinal IFN-gamma producing T cell responses induced by human rotavirus infection and vaccines are correlated with protection against rotavirus diarrhea in gnotobiotic pigs. Vaccine 2008, 26(26):3322-3331.
111. Clark HF, Offit PA, Vidor E: Rotavirus Vaccines. In Vaccines Edited by: Plotkin S, Orenstein WA, Offit PA. Saunders-Elsevier; 2008:715-734.
112. Azevedo MS, Yuan L, Iosef C, Chang KO, Kim Y, Nguyen TV, et al.: Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection. Clin Diagn Lab Immunol 2004, 11(1):12-20.
113. Mattapallil JJ, Roederer M: Mucosa and vaccine-induced immune protection in nonhuman primates. Current Opinion in HIV and AIDS 2008, 3:387-392.
114. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, Bwayo JJ, et al.: HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008, 22(6):727-735.
115. Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, Schiller JT, Lowy DR, et al.: Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005, 23(28):3634-3641.
116. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, Sun JB, et al.: Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007, 25(51):8598-8610.
117. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, et al.: Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008, 82(15):7369-7378.
118. Pan CH, Nair N, Adams RJ, Zink MC, Lee EY, Polack FP, et al.: Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin Vaccine Immunol 2008, 15(4):697-706.
119. Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, et al.: Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006, 348(2):341-353.
120. Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, Kano M, et al.: Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004, 199(12):1709-1718.
121. Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, Florese RH, et al.: Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 2006, 353(1):83-98.
122. Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, Hinkula J, et al.: DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007, 25(32):5968-5977.
123. Robert-Guroff M: Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007, 18(6):546-556.
124. Patterson LJ, Robert-Guroff M: Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther 2008, 8(9):1347-1363.
125. Patterson LJ, Beal J, Demberg T, Florese RH, Malkevich N, Venzon D, et al.: Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Virology 2008, 374(2):322-337.
126. Burton DR: Antibodies, viruses and vaccines. Nat Rev Immunol 2002, 2(9):706-713.
127. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449(7158):101-104.
128. Weinhold KJ: Anti-HIV-1 ADCC: clinical and therapeutic implications. Biotechnol Ther 1991, 2(1–2):147-157.
129. Koff WC, Parks CL, Berkhout B, Ackland J, Noble S, Gust ID: Replicating viral vectors as HIV vaccines Summary Report from IAVI Sponsored Satellite Symposium, International AIDS Society Conference, July 22, 2007. Biologicals 2008.
130. Kawada M, Tsukamoto T, Yamamoto H, Iwamoto N, Kurihara K, Takeda A, et al.: Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol 2008, 82(20):10199-10206.
131. Kutzler MA, Weiner DB: DNA vaccines: ready for prime time? Nat Rev Genet 2008, 9(10):776-788.
132. Lu S: Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 2008, 4(6):449-452.
133. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, et al.: An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008, 205(1):63-77.
134. Stahl-Hennig C, Kuate S, Franz M, Suh YS, Stoiber H, Sauermann U, et al.: Atraumatic oral spray immunization with replication-deficient viral vector vaccines. J Virol 2007, 81(23):13180-13190.
135. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, et al.: The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 2007, 178(7):4424-4435.
136. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, et al.: HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006, 7(1):19-23.
137. Mansfield K, Lang SM, Gauduin MC, Sanford HB, Lifson JD, Johnson RP, et al.: Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol 2008, 82(8):4135-4148.
138. Nolan KM, Jordan AP, Hoxie JA: Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J Virol 2008, 82(2):664-673.
139. Cox KS, Clair JH, Prokop MT, Sykes KJ, Dubey SA, Shiver JW, et al.: DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J Virol 2008, 82(16):8161-8171.